Amid aprocitentan’s regulatory review, Idorsia is buying back the hypertension drug from J&J in $350M deal
Johnson & Johnson’s Janssen is handing back the global development and commercialization rights to the hypertension candidate aprocitentan to Idorsia. This new agreement effectively undoes a deal from 2017, when J&J paid Idorsia $230 million for commercialization rights for the asset.
Idorsia is set to pay J&J 306 million Swiss francs ($343.9 million) pending revenues. J&J would be entitled to receive 30% of any out-licensing or divestment deals specific to aprocitentan, as well as 10% of a separate deal related to an Idorsia asset once aprocitentan has received a regulatory nod. J&J would also be entitled to low- to mid-single digit royalties.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
